Description

NR 566 Week 6 Quiz 

1. Question: A patient taking an MAOI is prescribed venlafaxine for another medical condition. What should the healthcare provider do with the MAOI?
2. Question: Which of the following populations is cautioned to be particularly monitored for an increased risk of suicide when taking SSRIs?
3. Question: Which of the following symptoms is characteristic of neuroleptic malignant syndrome (NMS), a rare but serious reaction to antipsychotic medications?
4. Question: A patient with depression presents with significant somnolence after starting mirtazapine therapy. Which of the following measures should be taken to manage this side effect?
5. Question: A patient presents with symptoms of severe headache, nausea, and profuse sweating after consuming aged cheese while taking an MAOI. What should the healthcare provider suspect?
6. Question: A patient with schizophrenia presents with extrapyramidal side effects after starting a first-generation antipsychotic. Which category of FGAs is most likely responsible for these side effects?
7. Question: A 30-year-old patient with bipolar disorder is beginning lithium therapy. Baseline labs are within normal limits. After 10 days, the patient reports nausea, fine hand tremors, and mild confusion. What is the most appropriate next step in management?
8. Question: A patient with postpartum depression is breastfeeding their newborn. They express concern about the safety of antidepressant use while breastfeeding. Which antidepressant would be considered safest for use while breastfeeding?
9. Question: A patient with suspected ADHD starts atomoxetine but reports no improvement after 5 days. What should the clinician explain?
10. Question: A patient with bipolar disorder is being started on lithium What baseline data should be assessed before initiating lithium treatment?
11. Question: A patient with major depression has not responded to treatment with SSRIs or TCAs. What alternative medication option should the healthcare provider consider?
12. Question: Which of the following is a characteristic feature of acute dystonia, a type of extrapyramidal symptom?
13. Question: How long should drug therapy for transient insomnia typically last?
14. Question: A patient with depression experiences persistent symptoms despite 6 weeks of treatment with an SSRI. What should the healthcare provider consider as the next best step in management?
15. Question: What class of medications is considered first-line for most patients with Social Anxiety Disorder (SAD)?
16. Question: A patient is prescribed a hypnotic for transient insomnia. What advice should the healthcare provider give to minimize the risk of drug-dependency insomnia?
17. Question: A patient with schizophrenia presents with extrapyramidal symptoms. What drug category is most likely responsible?
18. Question: A patient with depression is being treated with an SSRI but continues to experience persistent symptoms. What is the next best step?
19. Question: What class of medications is considered first-line for most patients with Social Anxiety Disorder (SAD)?
20. Question: A patient is prescribed a hypnotic for transient insomnia. What advice should be given to minimize dependency?
    

    ---

NR 566 Week 6 Quiz 

1. Question: A patient with suspected ADHD starts atomoxetine but reports no improvement after 5 days. What should the clinician explain?
2. Question: A patient with depression presents with significant somnolence after starting mirtazapine therapy. Which of the following measures should be taken to manage this side effect?
3. Question: A patient with major depression has not responded to treatment with SSRIs or TCAs. What alternative medication option should the healthcare provider consider?
4. Question: What class of medications is considered first-line for most patients with Social Anxiety Disorder (SAD)?
5. Question: A 30-year-old patient with bipolar disorder is beginning lithium therapy. Baseline labs are within normal limits. After 10 days, the patient reports nausea, fine hand tremors, and mild confusion. Which of the following is the most appropriate next step in management?
6. Question: A patient is prescribed a hypnotic for transient insomnia. What advice should the healthcare provider give to minimize the risk of drug-dependency insomnia?
7. Question: A patient with bipolar disorder is being started on lithium therapy. What baseline data should be assessed before initiating lithium treatment?
8. Question: A patient with schizophrenia presents with extrapyramidal side effects after starting a first-generation antipsychotic. Which category of FGAs is most likely responsible for these side effects?
9. Question: A patient presents with symptoms of severe headache, nausea, and profuse sweating after consuming aged cheese while taking an MAOI. What should the healthcare provider suspect?
10. Question: Which class of medications is the best choice to use as adjunctive therapy to mood stabilizers for the short-term management of severe mania in bipolar disorder?
11. Question: A patient with depression experiences significant weight gain and sexual dysfunction while receiving an SSRI. What alternative antidepressant option may be appropriate for this patient?
12. Question: A patient with depression experiences persistent symptoms despite 6 weeks of treatment with an SSRI. What should the healthcare provider consider as the next best step in management?
13. Question: Which of the following is a characteristic feature of acute dystonia, a type of extrapyramidal symptom?
14. Question: Which factor primarily influences the selection of antidepressants among drugs with nearly equal efficacy?
15. Question: A patient taking an MAOI is prescribed venlafaxine for another medical condition. What should the healthcare provider do with the MAOI?
16. Question: A patient presents with symptoms of serotonin syndrome after starting fluoxetine therapy. What is the appropriate management strategy for this patient?
17. Question: Which of the following symptoms is characteristic of neuroleptic malignant syndrome (NMS), a rare but serious reaction to antipsychotic medications?
18. Question: Which of the following populations is cautioned to be particularly monitored for an increased risk of suicide when taking SSRIs?
19. Question: A patient with postpartum depression is breastfeeding their newborn. They express concern about the safety of antidepressant use while breastfeeding. Which antidepressant would be considered safest for use while breastfeeding?
20. Question: How long should drug therapy for transient insomnia typically last?
    

    ---

NR 566 Week 6 Quiz – Review Questions & Answers

1. Question: How does atomoxetine work as a nonstimulant drug for ADHD?
2. Question: Why might guanfacine be preferred for a child with ADHD and a history of hypertension?
3. Question: How do amphetamines cause excessive vasoconstriction leading to hypertension?
4. Question: Why is it important to evaluate cardiovascular symptoms and assess for dysrhythmias in patients on amphetamines?
5. Question: How do amphetamines’ peripheral actions contribute to cardiovascular effects such as cardiac stimulation and vasoconstriction?
6. Question: Why is gradual tapering of amphetamine doses important to prevent withdrawal symptoms?
7. Question: How do amphetamines help treat narcolepsy?
8. Question: Why do antidepressant drugs carry a black box warning for increased risk of suicide, especially in younger populations?
9. Question: What is the recommended duration of treatment continuation after achieving remission of depressive symptoms, and why?
10. Question: What are the options for managing treatment-resistant depression when an initial antidepressant is ineffective?
11. Question: What new-onset symptoms might indicate the emergence of suicidality in patients on antidepressants?
12. Question: Why does antidepressant therapy typically take 6 to 8 weeks for maximal responses to develop?
13. Question: What is the major advantage of buspirone over benzodiazepines for long-term therapy?
14. Question: How can drugs that inhibit CYP2B6 affect bupropion levels and increase the risk of seizures?
15. Question: How does bupropion’s mechanism of action differ from that of SSRIs?
16. Question: Why are lithium and valproate preferred for the acute management of severe manic symptoms in bipolar disorder?
17. Question: What is the primary goal of long-term preventive treatment in bipolar disorder?
18. Question: Why are tricyclic antidepressants not recommended for the treatment of bipolar disorder?
19. Question: How does FGA therapy lead to gynecomastia in males?
20. Question: What does the black box warning for antipsychotic drugs in older adults with dementia-related psychosis indicate?
21. Question: Why is tardive dyskinesia considered the most troubling extrapyramidal reaction associated with long-term FGA therapy?
22. Question: How do first-generation antipsychotics cause adverse effects through receptor blockade?
23. Question: What are the symptoms of neonatal withdrawal from antipsychotic drugs, and why is it important to recognize them?
24. Question: What are the hallmark features of neuroleptic malignant syndrome (NMS), and why is prompt recognition important?
25. Question: What is the primary goal of long-term therapy with first-generation antipsychotics in schizophrenia?
26. Question: Why is schizophrenia the primary indication for the use of FGAs?
27. Question: What are the characteristic features of tardive dyskinesia, and why is it important to recognize them?
28. Question: What is the typical timeline for therapeutic response to first-generation antipsychotics in schizophrenia?
29. Question: How is acute dystonia managed in patients on first-generation antipsychotics?
30. Question: How can lithium-induced polyuria be managed with amiloride?
31. Question: Why is fine hand tremor a common early adverse effect of lithium therapy?
32. Question: How do MAOIs exert their therapeutic effects by inhibiting monoamine oxidase-A? Why does clozapine carry a black box warning for agranulocytosis?
33. Question: Why is it important to recognize symptoms such as fever, sore throat, and fatigue in patients on clozapine?
34. Question: Why is significant weight gain a common adverse effect of clozapine therapy, and how can it be managed?
35. Question: How do serotonin-norepinephrine reuptake inhibitors (SNRIs) affect neurotransmitter levels?
36. Question: How do SNRIs and SSRIs compare in terms of efficacy for treating major depression?
37. Question: Why is it important to taper the dosage of venlafaxine gradually?
38. Question: Why is it important to monitor blood pressure in patients on venlafaxine?
39. Question: Why is the concurrent use of SSRIs and MAOIs contraindicated?
40. Question: How can switching to a different SSRI help manage persistent sexual dysfunction associated with fluoxetine therapy?